Understand the source comparison
Best Research Peptides for SIBO: Evidence Comparison
BPC-157 Epithelial repair, angiogenesis VEGF upregulation, NOS stabilisation Rodent models: 60% faster healing; human case reports positive 250–500 mcg SC daily Most relevant for barrier dysfunction SIBO LL-37 Antimicrobial membrane disruption Direct bacterici
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Epithelial repair, angiogenesis
- VEGF upregulation, NOS stabilisation
- Rodent models: 60% faster healing; human case reports positive
- 250–500 mcg SC daily
- Most relevant for barrier dysfunction SIBO
- LL-37
- Antimicrobial membrane disruption
- Direct bactericidal, LPS neutralisation
- Phase 2 IBD trial: 40% reduction in inflammation
- 2–5 mg topical/local delivery
- Strongest direct antimicrobial effect
- Thymosin Alpha-1
- Immune modulation, T-cell regulation
- Th1/Th17 balance, dendritic cell maturation
- IBS-D study: 34% permeability reduction
- 1.6 mg SC twice weekly
- Best for immune-compromised SIBO
- Beta-defensins
- Endogenous AMP production
- SCFA-mediated epithelial defense
- Observational: inversely correlated with dysbiosis
- N/A (endogenous only)
- Marker of gut health, not intervention